Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson's Disease? - PubMed (original) (raw)
Review
Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson's Disease?
Atbin Djamshidian et al. Mov Disord Clin Pract. 2015.
Abstract
Banisteriopsis caapi, a liana indigenous to the Amazon basin with metagnomigenic properties and possible anti-depressant effects is one of the natural sources of harmala alkaloids. A summary of early trials with extracts of Banisteriopsis caapi and Peganum harmala (from which harmine was first isolated) in the 1920s and 1930s on various forms of parkinsonism is given as well as a brief overview of the known pharmacological properties of harmine. Despite its earlier abandonment because of perceived weaker efficacy than solanaceous alkaloids like scopolamine and hyoscine we propose that harmine should be reconsidered as a potential rapidly acting anti-Parkinsonian agent.
Keywords: Banisteriopsis caapi; Parkinson's disease; harmine.
Figures
Figure 1
Banisteriopsis caapi (left) and Peganum harmala (right).
Figure 2
Harmine for postencephalitic parkinsonism and idiopathic PD was produced by Merck and available as capsules, suppository, and SC injections. Original harmine lyophilized powder and harmine vial for SC injections. Pictures taken at Merck (Darmstadt, Germany).
Similar articles
- Composition, standardization and chemical profiling of Banisteriopsis caapi, a plant for the treatment of neurodegenerative disorders relevant to Parkinson's disease.
Wang YH, Samoylenko V, Tekwani BL, Khan IA, Miller LS, Chaurasiya ND, Rahman MM, Tripathi LM, Khan SI, Joshi VC, Wigger FT, Muhammad I. Wang YH, et al. J Ethnopharmacol. 2010 Apr 21;128(3):662-71. doi: 10.1016/j.jep.2010.02.013. Epub 2010 Feb 26. J Ethnopharmacol. 2010. PMID: 20219660 Free PMC article. - Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson's disease.
Samoylenko V, Rahman MM, Tekwani BL, Tripathi LM, Wang YH, Khan SI, Khan IA, Miller LS, Joshi VC, Muhammad I. Samoylenko V, et al. J Ethnopharmacol. 2010 Feb 3;127(2):357-67. doi: 10.1016/j.jep.2009.10.030. Epub 2009 Oct 30. J Ethnopharmacol. 2010. PMID: 19879939 Free PMC article. - A rapid and simple method for the determination of psychoactive alkaloids by CE-UV: application to Peganum Harmala seed infusions.
Tascón M, Benavente F, Vizioli NM, Gagliardi LG. Tascón M, et al. Drug Test Anal. 2017 Apr;9(4):596-602. doi: 10.1002/dta.1989. Epub 2016 Jul 5. Drug Test Anal. 2017. PMID: 27377797 - Pharmacological and therapeutic effects of Peganum harmala and its main alkaloids.
Moloudizargari M, Mikaili P, Aghajanshakeri S, Asghari MH, Shayegh J. Moloudizargari M, et al. Pharmacogn Rev. 2013 Jul;7(14):199-212. doi: 10.4103/0973-7847.120524. Pharmacogn Rev. 2013. PMID: 24347928 Free PMC article. Review.
Cited by
- Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields.
Strauss D, Ghosh S, Murray Z, Gryzenhout M. Strauss D, et al. 3 Biotech. 2022 Dec;12(12):339. doi: 10.1007/s13205-022-03355-4. Epub 2022 Nov 4. 3 Biotech. 2022. PMID: 36340802 Free PMC article. Review. - Preliminary evidence of links between ayahuasca use and the corpus callosum.
Simonsson O, Bouso JC, Kurth F, Araújo DB, Gaser C, Riba J, Luders E. Simonsson O, et al. Front Psychiatry. 2022 Oct 26;13:1002455. doi: 10.3389/fpsyt.2022.1002455. eCollection 2022. Front Psychiatry. 2022. PMID: 36386967 Free PMC article. - Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.
Vargas DM, De Bastiani MA, Parsons RB, Klamt F. Vargas DM, et al. Mol Neurobiol. 2021 Apr;58(4):1517-1534. doi: 10.1007/s12035-020-02203-x. Epub 2020 Nov 19. Mol Neurobiol. 2021. PMID: 33211252 - Identification of biosynthetic genes for the β-carboline alkaloid kitasetaline and production of the fluorinated derivatives by heterologous expression.
Ueda S, Ikeda H, Namba T, Ikejiri Y, Nishimoto Y, Arai M, Nihira T, Kitani S. Ueda S, et al. J Ind Microbiol Biotechnol. 2019 May;46(5):739-750. doi: 10.1007/s10295-019-02151-z. Epub 2019 Feb 20. J Ind Microbiol Biotechnol. 2019. PMID: 30788639 - A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers.
Ables JL, Israel L, Wood O, Govindarajulu U, Fremont RT, Banerjee R, Liu H, Cohen J, Wang P, Kumar K, Lu G, DeVita RJ, Garcia-Ocaña A, Murrough JW, Stewart AF. Ables JL, et al. J Psychopharmacol. 2024 Oct;38(10):911-923. doi: 10.1177/02698811241273772. Epub 2024 Sep 20. J Psychopharmacol. 2024. PMID: 39301926 Free PMC article. Clinical Trial.
References
- Sanchez‐Ramos JR. Banisterine and Parkinson's disease. Clin Neuropharmacol 1991;14:391–402. - PubMed
- Serrano‐Dueñas M, Cardozo‐Pelaez F, Sánchez‐Ramos J. Effects of Banisteriopsis caapi extract on Parkinson's disease. Sci Rev Altern Med 2001;5:129–134.
- Foley P. Beans, roots and leaves: a brief history of the pharmacological therapy of parkinsonism. Wurzbg Medizinhist Mitt 2003;22:215–234. - PubMed
- Wolfes O, Ivers O. Über Harmin, ein dem Banisterin (Yagein) identisches Alkaloid. Merck's Jahresbericht, 1928.
- de Boor W. Weitere Alkaloide mit geringer praktischer. Bedeutung Pharmakopsychol Psychopathol. 1956.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources